CTA
VRTX icon

Carillon Tower Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History

Carillon Tower Advisers’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$3.64M Sell
15,400
-600
-4% -$138K 0.02% 433
2020
Q3 		$4.35M Buy
16,000
+8,000
+100% +$2.21M 0.06% 349
2020
Q2 		$2.32M Buy
+8,000
New +$2.17M 0.02% 432

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Carillon Tower Advisers's VRTX Position: Q4 2020 in Review

Carillon Tower Advisers reduced its Vertex Pharmaceuticals (VRTX) stake by 3.8% in Q4 2020, selling an estimated $138K and leaving 15,400 shares worth $3.64M. The position accounts for 0.02% of the portfolio, ranked #433.

Carillon Tower Advisers first reported a position in VRTX in Q2 2020 and has held it in 3 quarters since. The position peaked at $4.35M in Q3 2020. 971 funds tracked by Wall St. Rank hold VRTX as of Q4 2020.

  • Carillon Tower Advisers held 15,400 shares of Vertex Pharmaceuticals worth $3.64M as of Q4 2020.
  • Carillon Tower Advisers sold 600 Vertex Pharmaceuticals shares in Q4 2020, an estimated $138K.
  • Vertex Pharmaceuticals made up 0.02% of Carillon Tower Advisers's portfolio in Q4 2020, its #433 holding.
  • Carillon Tower Advisers first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 3 quarters since.
  • Carillon Tower Advisers's Vertex Pharmaceuticals position peaked at $4.35M in Q3 2020.
  • 971 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.